Mar 13, 2023 / 03:20PM GMT
Suraj Kalia - Oppenheimer & Co. Inc., Research Division - MD & Senior Analyst
Good morning, everyone. It's a pleasure to have all of you on the call this morning, and I'm especially pleased to have Rob Douglas, CEO of ResMed on the line with us. Rob, I'll let you have the floor, and then we'll jump into the fireside chat.
Robert A. Douglas - ResMed Inc. - President & COO
Thanks Suraj. Just a brief intro to ResMed. We're the global leader in connected and digital health. We've got 3 main businesses; sleep apnea -- untreated sleep apnea or sleep suffocation, respiratory care, treating COPD and other chronic diseases and our Software as a Service businesses providing the operating system for the providers of out-of-hospital care services now around the world. These are all incredible businesses with really strong growth profiles. The number of patients around the world with sleep apnea is approaching 1 billion people, only a tiny fraction of those people are even aware that they have the condition and the treatment would be a good option for them. And
Resmed Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot